November 08, 2024--Positive high-level results from the Phase III WAYPOINT ... with nasal polyps (CRSwNP [nasal polyps]) showed that AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab) demonstrated ...

GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications. The submitted ...

GSK plc announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications. The submitted indications are for ...

AZ and Amgen tried and failed to develop tezepelumab as a therapy for atopic dermatitis, chalking up one failed phase 3 trial in 2017, but have continued to develop the drug for other indications ...

If approved, depemokimab will be the first ultra-long-acting biologic with 6-month dosing Submissions based on data from positive SWIFT and ANCHOR trials SWIFT-1 and -2 showed depemokimab reduced ...

Amgen and AstraZeneca haven't won approval or announced a price for their severe asthma therapy tezepelumab should it reach the market, but the ICER in the US maintains it will probably not be ...

What is the current share price of Waypoint REIT Limited (WPR)? Waypoint REIT Limited's (WPR) current share price is $2.44. This constitutes a price movement of 2.09% when compared to the share price ...

Kaivan Khavandi, SVP at GSK, stated, "Simultaneous regulatory submissions for two indications highlight our confidence in depemokimab to help reduce the burden of both asthma and CRSwNP for ...

Similarly, the ANCHOR trials showed that depemokimab effectively reduced nasal polyp size and obstruction in CRSwNP patients compared to placebo. Depemokimab, a monoclonal antibody targeting ...

The annualized rate of moderate or severe COPD exacerbations at 52 weeks was 1.75 for tezepelumab compared with 2.11 for placebo. Tezepelumab did not significantly decrease the annualized rate of ...

Abstract: Chronic rhinosinusitis with nasal polyps (CRSwNP), as one of the most common chronic nasal inflammations, has been a major research focus in the field of rhinology due to its complex and ...

Patients with unilateral chronic rhinosinusitis with nasal polyps (CRSwNP) tend to have less severe disease than those with bilateral nasal polyps and generally have better outcomes than those with ...